Safety and Adverse Events of Dose-dense Chemotherapy for Breast Cancer in Japanese Patients

Key Points

• To evaluate the safety and adverse events of dose-dense chemotherapy in high-risk breast cancer patients in Japan.
• Retrospective analysis of 127 Japanese patients undergoing dose-dense chemotherapy from June 2016 to March 2023.
• Treatment included pegfilgrastim, AC (doxorubicin and cyclophosphamide), and PTX (paclitaxel) administered bi-weekly for four cycles.
• Completion rates of dose-dense AC and PTX were monitored along with adverse events.
• The completion rate for dose-dense chemotherapy was 85.8%.
• Main adverse events included liver dysfunction in 4 cases, rash in 3 cases, drug-induced pneumonia in 3 cases, and anemia in 2 cases.
• Grade 1 or higher liver dysfunction occurred in over 60% of patients, but many continued treatment without delays.